Molecular targeted therapy in ovarian cancer: what is on the horizon?

Hdl Handle:
http://hdl.handle.net/10147/207071
Title:
Molecular targeted therapy in ovarian cancer: what is on the horizon?
Authors:
Kalachand, Roshni; Hennessy, Bryan T; Markman, Maurie
Affiliation:
Department of Medical Oncology, Beaumont Hospital, Dublin, Ireland., roshnikalachand@physicians.ie
Citation:
Drugs. 2011 May 28;71(8):947-67. doi: 10.2165/11591740-000000000-00000.
Journal:
Drugs
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207071
DOI:
10.2165/11591740-000000000-00000
PubMed ID:
21668036
Abstract:
Over the past two decades, empirical optimization of cytotoxic chemotherapy combinations and surgical debulking procedures have improved outcomes and survival in epithelial ovarian cancer. Yet, this disease remains the fifth leading cause of cancer-related deaths in the US, as cure rates seem to have reached a plateau at approximately 20% with conventional chemotherapy. Novel high-throughput genomic and proteomic analyses have improved the molecular understanding of ovarian carcinogenesis, thereby providing a vast array of new potential drug targets with complex signalling interactions. In order to yield the most significant impact on disease outcome, it is necessary to carefully select, and subsequently target, the driving molecular pathway(s) within a tumour or tumour subtype, which are most likely to correspond to high-frequency mutations and genomic aberrations. The identification of biomarkers predictive of response to targeted therapy is essential to avoid poor responses to potentially useful drugs in unselected trial populations. With some promising, albeit early, phase III data on the angiogenesis inhibitor bevacizumab, exciting new opportunities lie ahead with the ultimate goal of personalizing therapies to individual tumour profiles.
Language:
eng
ISSN:
0012-6667 (Print); 0012-6667 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorKalachand, Roshnien_GB
dc.contributor.authorHennessy, Bryan Ten_GB
dc.contributor.authorMarkman, Maurieen_GB
dc.date.accessioned2012-02-01T09:58:33Z-
dc.date.available2012-02-01T09:58:33Z-
dc.date.issued2012-02-01T09:58:33Z-
dc.identifier.citationDrugs. 2011 May 28;71(8):947-67. doi: 10.2165/11591740-000000000-00000.en_GB
dc.identifier.issn0012-6667 (Print)en_GB
dc.identifier.issn0012-6667 (Linking)en_GB
dc.identifier.pmid21668036en_GB
dc.identifier.doi10.2165/11591740-000000000-00000en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207071-
dc.description.abstractOver the past two decades, empirical optimization of cytotoxic chemotherapy combinations and surgical debulking procedures have improved outcomes and survival in epithelial ovarian cancer. Yet, this disease remains the fifth leading cause of cancer-related deaths in the US, as cure rates seem to have reached a plateau at approximately 20% with conventional chemotherapy. Novel high-throughput genomic and proteomic analyses have improved the molecular understanding of ovarian carcinogenesis, thereby providing a vast array of new potential drug targets with complex signalling interactions. In order to yield the most significant impact on disease outcome, it is necessary to carefully select, and subsequently target, the driving molecular pathway(s) within a tumour or tumour subtype, which are most likely to correspond to high-frequency mutations and genomic aberrations. The identification of biomarkers predictive of response to targeted therapy is essential to avoid poor responses to potentially useful drugs in unselected trial populations. With some promising, albeit early, phase III data on the angiogenesis inhibitor bevacizumab, exciting new opportunities lie ahead with the ultimate goal of personalizing therapies to individual tumour profiles.en_GB
dc.language.isoengen_GB
dc.titleMolecular targeted therapy in ovarian cancer: what is on the horizon?en_GB
dc.contributor.departmentDepartment of Medical Oncology, Beaumont Hospital, Dublin, Ireland., roshnikalachand@physicians.ieen_GB
dc.identifier.journalDrugsen_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.